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Abstract 
 
Introduction and aim: To evaluate adherence to antihypertensive treatment in rural South Africa and 
identify potential determinants given concerns with adherence and its impact in this priority disease 
area. Method: Face-to-face interviews with hypertensive patients and rating their adherence to 
treatment using defined categorised responses. Associations between adherence and patient 
characteristics assessed and sensitivity analyses performed. Results: 54.6% of patients were 
adherent to treatment. Controlled blood pressure (OR = :=2.1; 95% CI [:1.1, -3.8]; p = 0.019), 
comorbidity (OR = :=2.0; 95% CI [: 1.1, -3.6]; p = 0.032) and smoking (OR = :=0.3; 95% CI [:0.1, -0.8]; 
p = 0.018) were associated with adherence. Conclusion: Adherence and BP control were 
suboptimal, only smoking was an independent risk factor for adherence. Adherent patients were twice 
as likely to have controlled BP, although results were sensitive to the definition of adherence. 
Initiatives are in place to improve adherence, which will be monitored. 
 
Introduction 
 
Hypertension is a major public health concern worldwide [1−5], with an estimated 17.7 million people 
worldwide in 2008 dying annually from cardiovascular disease (CVD), accounting for more than a 
third of all deaths due to non-communicable diseases (NCDs) [2, 3]. Of these 17.7 million deaths, 
hypertension currently accounts for 9.4 million (50%) deaths [1−2]. Patients living in low and middle 
income countries (LMICs) account for the majority of patients with hypertension worldwide as well as 
deaths due to uncontrolled blood pressure [1, 2, 4−7]. The World Health Organization (WHO) 
estimates that up to three quarters of all deaths in Africa could soon be due to hypertension if not 
adequately addressed [2, 3]. The greatest prevalence worldwide for hypertension is in the African 
Region, where up to 46% of adults aged 25 or over in 2008  had hypertension [2], with up to three 
quarters or more of hypertensive patients currently failing to achieve target blood pressure (BP) goals 
[7−12]. It is perceived that a lack of adherence to medication is the major causative factor for 
uncontrolled hypertension [1, 4, 6−8, 11-16]. Non-adherence to medicines affects up to 30-50% of 
patients or more with chronic conditions including hypertension [8, 17, 18], with poor adherence levels 
seen even in the first year of treatment [12, 19, 20]. The consequences of non-adherence to 
antihypertensive medication are not only poorer health outcomes, including higher cardiovascular 
mortality, but also increased health care costs and poorer economy to the country [1, 17,18, 20−22]. 
As a result, the WHO and others recognise the burden of medication non-adherence as an important 
public health concern, necessitating urgent action [1, 2, 14, 20, 23].  
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In South Africa, NCDs are a common reason for patients to visit primary health care (PHC) facilities, 
with over 50% or more of adults in South Africa potentially having hypertension [24−26].   Currently 
over 80% of the population in South Africa are treated in the public health sector, where there is a 
high burden of NCDs [24, 26]. Rates of hypertension are rising in South Africa, with hypertension now 
accounting for the greatest reason why patients with NCDs visit  PHC facilities, enhanced by high 
levels of overweight and obesity among the population [26, 27]. In addition, hypertension was the 
sixth leading cause of death in South Africa in 2016 accounting for 4.4% of deaths [28]. Currently 
there are limited attempts to address this, although the situation is changing with ongoing initiatives to 
improve the management of patients with chronic diseases in South Africa [25, 26, 29]. 
 
Factors affecting adherence are complex [1, 6], and can include patients’ beliefs and perceptions 
about the disease and treatment, medication side-effects, treatment regimens, treatment support 
including family members, unintentional behaviour such as patients forgetting to take their medication 
or intentional behaviour as in the case of certain beliefs and perceptions [1, 6, 11, 12, 14, 30].  Other 
factors affecting adherence include unrealistic expectations of treatment such as a cure for their 
hypertension, depression from being newly diagnosed or knowing that hypertension is not curable, as 
well as the use of herbal preparations [9, 10, 12, 31]. Unavailability of antihypertensive medicines at 
PHC facilities, a low level of formal education, and other factors such as the distance to treatment 
facilities, medication costs, and the availability of professional guidance, are also associated with non-
adherence to treatment [7, 9, 12, 16, 30, 32].  
 
The cornerstone of BP control in hypertensive patients is adherence to both pharmacological and 
non-pharmacological management of hypertension [9, 10, 12, 31, 33−35]. Non-pharmacological 
treatments include reducing salt intake, improving diets and increasing exercise levels [12, 13, 34]. 
Adherence to chronic medication results in better healthcare outcomes for patients, in this case better 
BP control [12, 14, 33, 36].  
 
As a result, health care providers should have the necessary knowledge and skills to assess 
adherence, and to assist patients to improve their adherence to antihypertensive treatment where this 
is a concern [12, 24, 37, 38]. Successful outcomes in the management of hypertension require 
information on patient medication-taking behaviour, factors hindering adherence where these are a 
concern, as well as knowledge about patients’ beliefs and perceptions concerning their 
antihypertensive medication [12, 21, 35].  
 
In view of this, the aim of this study was to determine the level of adherence to antihypertensive 
medication in practice as well as explore a possible relationship between adherence and factors 
affecting adherence levels in South Africa. This is increasingly important in South Africa with the 
implementation of the Central Chronic Medicines Dispensing and Distribution (CCMDD) programme 
[26]. The CCMDD programme aims to improve access to chronic medicines as a two-month supply of 
patients’ medicines are delivered to the nearest preferred pick-up point along with physician 
consultations every six months [39, 40]. In addition, the first Remote Pharmacy Dispensing Unit 
(RPDU) was recently launched by the Gauteng Health Department, in cooperation with a private 
provider, for service delivery closer to a patient’s workplace or home to enhance medicine access. 
Under this scheme, there is the potential for internet interaction between patients and tele-
pharmacists. In addition, the date for the next collection is shown on the receipt the patient receives 
when collecting their medication with reminders sent by SMS, with late collections highlighted to aid 
adherence in patients with chronic diseases [41,42].  However, both schemes limit contact between 
the patient and health care professionals although better with the RPDU scheme. Furthermore, there 
are also concerns with the current level of information seeking behaviour among South Africans [43]. 
Consequently, the findings of this study can be used as a baseline of patients’ adherence to chronic 
medicines prior to enrolment on the CCMDD programme to help plan future interventions to further 
improve chronic disease management in South Africa. 
 
Method 
 
Study setting  
The study was conducted at 50 PHC facilities, conveniently selected from the 120 PHC facilities in the 
Vhembe District. These facilities were accessible to pharmacists visiting the facilities as part of their 
practice, and who also served as data collectors. The Vhembe District is a rural district and the most 
northern district of Limpopo Province, in South Africa. Limpopo Province is also the most northern 
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province in the country. Consequently, in view of more limited access to healthcare facilities in rural 
areas of South Africa versus urban areas and less monitoring of patients, it is vital that adherence 
rates are kept high in these areas through pertinent initiatives.  There will now be even less contact 
between health care professionals and hypertensive patients with the introduction of CCMDD [25, 26], 
although potentially better with remote personnel under the RPDU scheme [41,42]. Consequently, our 
desire to initiate this research in this region. Health care services in the Vhembe District are delivered 
by district hospitals, PHC facilities (PHC clinics and community health centres) and mobile services.  
 
Study design 
A cross-sectional descriptive design was used as part of an operational study to measure adherence 
to antihypertensive treatment amongst chronic hypertensive patients collecting their medication from 
PHC facilities. Adherence data were collected at one time point between June and August 2015. 
Considering that both direct and indirect methods of measuring adherence have their own advantages 
and disadvantages and currently that there is no gold standard method, adherence was assessed 
through patient self-reporting using structured face-to-face interviews. Patient self-reporting is 
convenient to use in daily practice both in cost terms and practicability [44]. Evidence also showed 
that cognitive testing of self-reported adherence items revealed that participants felt more comfortable 
and confident with words compared to numbers, and the cognitive process of estimation matched 
better with the words than numbers [45]. Patients’ blood pressure (BP), taken by clinic staff on the day 
of the interview, was obtained from their file, while other patient characteristics were collected during 
the interview.  
 
Study sample and recruitment 
Due to the operational nature of the study, convenient and consecutive sampling was used by 
pharmacists visiting PHC facilities to recruit 1−15 hypertensive patients, ≥ 18 years, and on chronic 
antihypertensive treatment, at each of the 50 PHC facilities on the day of the visit. The 50 clinics 
included facilities from all different geographical parts in all the municipalities in the Vhembe District. 
The study population was randomly selected from hypertensive patients who had been on treatment 
for more than 6 months and were consulting on the day of data collection. Data collectors would 
identify any hypertensive patients sitting in the queue for consultation by checking their files and 
subsequently recruit them to participate in the study. Any hypertensive patients who had their vital 
signs taken on that day, and who met the inclusion criteria, were recruited.  A total of 253 
hypertensive patients were subsequently enrolled. Two patients lacked some of their adherence data 
and were subsequently excluded from the analysis, leaving 251 patients for complete analysis. 
Pregnant patients and patients who were severely ill on the day of data collection were excluded from 
the sample as this is a common practice in such research [46]. In addition, excluded for logistical 
reasons such as the fact that they might not be in a position to sit for a period of time to complete the 
interview, in addition to their consultation time. Patients were recruited after the collection of their 
medicines and the recording of their vital signs.  Resting BP, taken on the day of the interview by 
nurses trained on the procedure, were recorded from patients’ files onto the questionnaire. The 
resting BP was measured on either arm of the patient using a digital automatic BP monitor or a 
sphygmomanometer, depending on their availability at the PHC facility. Patients’ height and weight 
were also measured on the day of the interview using a mobile stadiometer and a column standing 
scale. On completion of the interview, the next available patient meeting the inclusion criteria was 
recruited. 
 
Data collection procedures and data collection instrument 
The structured questionnaire was administered by trained data collectors, who were all pharmacists. 
Adherence was assessed using a self-reported rating scale with six pre-defined categorised 
responses, i.e. excellent, very good, good, fair, poor and very poor, previously used in adherence 
studies [1, 45, 47]. The scale measured the ability of patients in taking their medication in the last 30 
days prior to the interview, according to these six categories. Published evidence suggests that 
patients may provide better estimates of adherence on a 30-day recall compared to a three-day or 
seven-day recall period [45, 48].   
 
The questionnaire also collected information on factors that previously have been shown to be 
associated with adherence. These included gender, education, level of BP control, comorbidities, 
family history, knowledge of hypertension management, physical activity and smoking, in line with 
previous studies [1, 12, 14, 36, 49]. With the exception of vital signs, such as BP and body mass 
index (BMI), all the information was received from self-reporting. The questionnaire was tested in a 
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pilot study amongst 20 hypertensive patients on treatment prior to the actual study to ascertain the 
suitability and feasibility for the study population. Amendments were made prior to commencement of 
data collection to enhance the robustness of the final questionnaire. Responses to the questions in 
the interview and the BP reading taken on the day of the interview were recorded on the 
questionnaire.  
 
Data analysis 
Data were captured on Microsoft Excel™ spread sheets and cross-checked for accuracy and 
correctness. Discrepancies were rectified prior to commencement of data analysis. Data were 
analysed using SAS® version 9.4.  
 
Descriptive statistics were used to summarise the study variables using frequencies and proportions 
for categorical variables and mean with standard deviation (SD) for continuous variables. For the 
main analysis, adherent patients were defined as those who rated their adherence over the past 30 
days as excellent, whilst non-adherence refers to those who rated their adherence as either very 
good, good, fair, poor or very poor. This categorisation was used based on the fact that excellence 
was translated to ≥80% adherence. This is because at least 80% and above of antihypertensive 
medication adherence is significantly associated with controlled BP [1, 12, 30]. Another basis for 
these categorisation was the assumption that patients exaggerate their responses based on their 
perceptions about the interview [21], and as such the authors assumed that patients who rated 
themselves ‘excellent’, either exaggerating or not, were likely to be adherent to ≥80% of their doses.  
 
A univariate association between adherence (dependant variable) and patient characteristics (socio-
demographic and hypertension-related factors) was tested using the Chi-square test. For statistical 
significance, a two-sided p-value ≤ 0.05 was accepted. Cramér’s V statistic was used to test the 
practical significance of these associations, with a value of 0.1 indicating a small effect, 0.3 a medium 
effect and 0.5 a large effect.   
 
Adjusted associations between adherence and study covariates was assessed using a multivariate 
logistic regression with ‘adherent’ defined as an ‘excellent’ rating. Odds ratios (OR) and 95% 
confidence intervals (95% CI) were calculated. In order to assess whether using an ‘excellent’ rating 
to classify patients as adherent had any impact on the study results, we conducted sensitivity 
analyses whereby we used another two different rating definitions for classifying patients as adherent; 
firstly patients who rated their adherence as either ‘excellent’, or ‘very good’ were classified as 
adherent; and secondly patients who rated their adherence cover as either ‘excellent’, ‘very good’ or 
‘good’ were classified as adherent. 
 
Ethical considerations   
The Medunsa Research Ethics Committee of the University of Limpopo (currently Sefako Makgatho 
Health Sciences University) provided ethical clearance for the study (Clearance number: 
MREC/H/27/2014:PG). Permission to conduct the study was obtained from the Limpopo Department 
of Health and Vhembe District Executive Manager. All patients provided written informed consent for 
participation. A unique study identification number was allocated to each patient and no personal 
details were recorded to maintain confidentiality. 
 
Results  
 
Blood pressure and self-reported adherence  
The study patients included 251 black hypertensive patients, the vast majority (82.4%; 206, n=251) 
being female with a mean age of 63 years (SD: 11.4). A third of patients were in the age group of 61-
70 years and 61.0% were married. More than half of the patients did not have any education, and only 
a small minority had a tertiary education.  Nearly two thirds of patients were on antihypertensive 
treatment for more than five years. All patients were treated with one or more antihypertensive drugs 
listed in the SA PHC Essential Medicines List and Standard Treatment Guidelines [26, 33].  These 
included hydrochlorothiazide 12.5 mg or 25 mg in the morning, enalapril 10mg once or twice daily, 
amlodipine 5mg daily and atenolol 50mg daily. However, only 46.3% of patients had controlled BP 
(SBP: <140 mmHg; DBP: <90 mmHg), while 7.9% had severe hypertension (SBP: ≥180 mmHg; DBP: 
≥110 mmHg) [40] on the day of the interview (Figure 1). Patients’ blood pressure on the day of the 
interview was used to determine whether their BP is controlled or not based on the fact that all the 
patients were on treatment for more than six months and that a once-off measurement of BP has 
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been used previously among hypertensive patients on treatment to determine if they are controlled or 
not [50]. 
 
Figure 1: Patients categorized according to blood pressure control (n=240) 
 
 
 
Figure 2 shows the proportion of patients per adherence rating. Only half of the patients (54.6%; 137, 
n=251) rated their adherence in the last 30 days as ‘excellent’ and were categorised as adherent. 
 
Figure 2: Proportion of patients per adherence rating during the past 30 days (n=251) 
 
 
 
Patient characteristics and adherence to anti-hypertensive medication 
Table 1 shows that with a univariate analysis there were only two significant associations between 
adherence to antihypertensive medication and patients’ basic demographics. The proportion of 
adherent patients among the educated group (62.2% of 111 patients) was significantly higher (p = 
0.036) than those among the non-educated group (48.9% of 139 patients). Secondly, only 31.0% of 
the 29 smokers were adherent, compared to 57.7% of the 222 non-smokers (p = 0.006). With 
borderline significance (p = 0.054), 61.9% of 118 patients with co-morbidities reported adherence 
compared to 49.6% of the 127 patients without any co-morbidity. There was no clear association 
between the period on antihypertensive medication or family history of hypertension and adherence 
rates. For all variables, the effect size of the association with adherence was small and not practically 
significant, as indicated by the Cramér’s V statistic. 
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Table 1: Patient characteristics by adherence category 
 
Patients characteristics 
Patients; n (%) 
p* 
Cramer’s 
V Overall Adherent Non-adherent 
Gender  
(n = 244) 
Female 201 (82.4) 110 (54.7) 91 (45.3) 0.896 
 
-0.008 
 Male  43 (17.6) 24 (55.8) 19 (44.2) 
Educational level  
(n = 250) 
Educated  111 (44.4) 69 (62.2) 42 (37.8) 0.036 
 
0.132 
No education  139 (55.6) 68 (48.9) 71 (51.1) 
Marital status  
(n = 244) 
Married  153 (62.7) 78 (51.0) 75 (49.0) 0.350 
 
-0.059 
 Single  91 (37.3) 52 (57.1) 39 (42.9) 
Blood pressure  
(n = 239) 
Controlled 112 (46.9) 67 (59.8) 45 (40.2) 0.143 
 
-0.094 
 Uncontrolled  127 (53.1) 64 (50.4) 63 (49.6) 
Period on 
antihypertensive 
treatment (n = 249) 
<1 year 16 (6.4) 7 (43.8) 9 (56.2) 0.368 0.056 
1 – 5 years 77 (30.7) 40 (51.9) 37 (48.1) 0.577 0.035 
>5 years 156 (62.2) 89 (57.1) 67 (42.9) 0.314 -0.063 
Family history of 
hypertension  
(n = 248) 
Known family history 121 (48.8) 71 (58.7) 50 (41.3) 0.224 
 
 
0.109 
 
 
Do not know 36 (14.5) 21 (58.3) 15 (41.7) 
No family history 91 (36.7) 43 (47.3) 48 (52.8) 
Physical activity  
(n = 248) 
Physical exercise 149 (60.1) 84 (56.4) 65 (43.6) 0.550 
 
-0.037 
 No physical exercise 99 (39.9) 52 (52.5) 47 (47.5) 
Co-morbidities 
(n = 245) 
Co-morbidity  118 (48.2) 73 (61.9) 45 (38.1) 0.054 -0.123 
 No co-morbidity 127 (51.8) 63 (49.6) 64 (50.4) 
Smoking  
(n = 251) 
Smokers  29 (11.5) 9 (31.0) 20 (69.0) 0.006 
 
0.170 
 Non-smokers  222 (88.5) 128 (57.7) 94 (42.3) 
Note: Data for some patients were not available, hence, difference in overall sample size; *Chi Square test 
 
Independent factors associated with adherence 
Only patients who had complete information on all the study covariates were included in a multivariate 
logistic regression analysis (n = 206). With the multivariate logistic regression analysis, when 
adherence was defined as an ‘excellent’ rating, significant factors that were independently associated 
with adherence to hypertensive medication were as follows: BP controlled (OR = 2.1; 95% CI [1.1, 8]; 
p = 0.019), comorbidity (OR = 2.0; 95% CI [1.1, 3.6]; p = 0.032) and smoking (OR = 0.3; 95% CI [0.1, 
0.8]; p = 0.018) (Table 2).  These results are however sensitive to the definition of adherence. When 
the definition of adherence was extended to a rating of ‘excellent’ and ‘very good’, only BP controlled 
(OR = 2.6; p = 0.013) was significantly associated with higher adherence, whereas when a wider 
definition of adherence is used (i.e. ‘excellent’, ‘very good’ and ‘good’), none of the factors were 
significantly associated with adherence.  
 
Table 2: Independent factors associated with adherence to antihypertensive treatment (n=206) 
 
Patient characteristics 
Adherent (‘excellent’ rating) 
Odds Ratio 95% CI p* 
Age  1.0 1.0, 1.0 0.422 
Male 1.3 0.6, 2.9 0.574 
Educated 1.4 0.7, 2.7 0.385 
Single 1.1 0.6, 2.1 0.775 
Blood pressure controlled 2.1 1.1, 3.8 0.019 
>5 years on treatment 0.7 0.3, 1.3 0.253 
Family history of hypertension 0.9 0.4, 1.7 0.688 
No physical activity 1.2 0.6, 2.2 0.573 
Co-morbidity  2.0 1.1, 3.6 0.032 
Smoking  0.3 0.1, 0.8 0.018 
*Multivariate logistic regression 
 
Discussion  
 
The reported proportion of patients rating themselves as adherent (54.6%) to antihypertensive 
medication in this study is similar to adherence rates reported at an outreach clinic in Nigeria (51%), 
PHC clinics in Hong Kong (55.1%) and a cardiovascular clinic in Tanzania (54%) [12, 51, 52]. Slightly 
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lower rates were reported in a Namibian study conducted in public sector PHC facilities, with less than 
half (42.5%) of patients reporting acceptable adherence levels of ≥80% [30].  On the other hand, this 
study finding is different from a previous study conducted at a clinic in a rural village of Limpopo 
Province, South Africa, where 80% of patients reported adherence to antihypertensive medication 
[53]. This may be because of the strict definition we used for adherence in this study, i.e. ‘excellent’ as 
opposed to ‘excellent’, ‘very good’ and ‘good’. 
 
There was no statistical significant relationship between gender and medication adherence in our 
study, which is different from the study conducted in China where higher adherence was found 
amongst males [54] as well as the meta-analysis of Nielsen et al where higher adherence rates were 
seen in women [1]. We are not sure of the reasons for this, but we will be investigating this further in 
future research. There was also no significant relationship between age and adherence, which is 
different to other studies [1], and again we will be investigating this further in future research projects. 
However, this study reaffirmed the findings of previous studies [1], which found that the level of 
education can have a direct influence on the extent of medication adherence. This is because a lack 
of formal education prevents patients from accessing and reading medicine information, as well as 
understanding labelled medication instructions [7, 9, 10, 12, 43, 55]. 
 
There was no significant relationship between marital status and adherence, which is similar to a 
study conducted in Ghana and Nigeria [9]. The lack of any statistical significant association between 
claimed adherence and the period on treatment, reminder (help) to take their medication by either a 
family member or friend, as well as perceptions and beliefs about hypertension and its treatment, are 
different from studies previously conducted in South Africa [37, 56] as well as wider [1]. The results 
also differ from studies conducted in Namibia and Nigeria, which reported that patients with good 
family support or social support from friends had better adherence than those without [30, 57, 58]. We 
will again be researching this further in the future as this again has implications for additional 
programmes to improve adherence rates among hypertensive patients in South Africa combined with 
the recent CCMDD programme and the recently launched PRDU programme. 
 
Previous evidence showed that there is a relationship between medication adherence and patients’ 
perceptions and beliefs of hypertension and its treatment [1, 12]; however, this was also not seen in 
our study. Perceptions that hypertension is not a chronic disease, is curable, and that it is curable 
through the use of herbal preparations, can also lead to non-adherence [9, 11], which must be 
factored into any future educational initiatives surrounding the treatment of patients with hypertension.  
 
Unlike other studies, we did not find a statistical significant relationship between the level of 
adherence and most of the studied variables. This lack of statistical significant relationship may be 
due to the fact that the patients in this study had similar demographic characteristics and experiences 
[59]. In addition, different methodologies have been used for measuring adherence rates [1, 12, 30] 
as well as concerns with the subjective measures of adherence with increased probability that 
patients provide answers that conform to their perceived expectations and those of the interviewer 
[18, 59]. Differences in study results may also be due to our sample size and the number of variables 
measured.  
 
A positive finding of this study was that there was no correlation between the period on anti-
hypertensive medication and medication adherence. This adds to what is already known, i.e. that a 
long period on treatment does not necessarily translate into better adherence to medication or control 
of BP [30, 60. The high adherence rate to recommended medicines in the SA Standard Treatment 
Guidelines is also very encouraging given variable adherence to guidelines that has been seen in 
practice [61 - 64]. This will be explored further in future studies to provide guidance to others.  
 
As seen, the multivariate logistic analysis results were very sensitive to the definition of adherence. 
For instance, when a wider definition of adherence (‘excellent’, ‘very good’ and ‘good’) was used, 
none of the factors were associated with adherence. When the definition of adherence was narrowed 
to ‘excellent’ and ‘very good’, only BP control was significantly associated with higher adherence. 
Whereas when adherence was limited to ‘excellent’, BP control, comorbidities and smoking were 
significantly associated with adherence. Only smoking and having a co-morbidity were independent 
risk factors for adherence to anti-hypertensive medications, with patients who smoke highly unlikely to 
adhere to treatment whereas patients with co-morbidities have a greater chance of adhering to 
treatment. Compared with non-adherent patients, adherent patients were twice as likely to have their 
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BP controlled, which is congruent with other studies that have demonstrated a higher proportion of 
uncontrolled BP in non-adherent patients and that adherent patients are up to five times more likely to 
have their blood pressure controlled [8, 49]. 
 
Further research is needed to identify additional contributing factors to non-adherence in South Africa 
to inform relevant strategies to improve adherence to treatment amongst hypertensive patients, 
especially with the advent of the CCMDD and PRDU programmes. It is recommended that health 
education should be provided to both educated and non-educated patients of all genders concerning 
the understanding of antihypertensive treatment, possible side-effects of medication, and the 
hypertension process, to improve medication adherence in the future, building on current 
programmes. We also believe patient education should be provided using different ways that may 
include counselling on medication as well as possibly written information depending on education 
levels that describes hypertension and its treatment, both pharmacologically and non-
pharmacologically, to promote good adherence.  
 
Based on their extensive training on medicines, pharmacists are in an ideal position to provide 
continuous counselling and education to patients [40, 47, 64, 65]. Patient counselling and education 
by pharmacists would not only improve adherence to medication, but also close this identified gap in 
the management of hypertension through providing continuous counselling and education as required 
by South African legislation [26, 34]. These are considerations for the future and will be part of future 
research programmes. 
 
Limitations 
 
We acknowledge that this study had a number of limitations. Firstly, it was only conducted in one 
district of the Limpopo Province in South Africa with a rural rather than urban population. Secondly, 
the unavailability of data in the files of some of the study patients compromised the sample size for 
certain variables. Thirdly, there were logistical issues during data collection such as unavailability of 
data collectors and patient availability. However, we believe our study does have interesting results to 
guide future activities to enhance the management of hypertension in South Africa, given current high 
prevalence rates and the priority to reduce morbidity, mortality and costs in this group. In addition, 
provide guidance alongside the recent CCMDD and PRDU programmes, especially in rural 
populations. 
 
Conclusion 
 
Both adherence and BP control were sub-optimal in this study population. Only half of the patients 
(54.6%) considered themselves as adherent to antihypertensive medication and less than half of the 
patients’ BP was controlled (46.3%). Only smoking was an independent risk factor for adherence to 
anti-hypertensive medication. Compared with non-adherent patients, adherent patients were twice as 
likely to have controlled BP and a co-morbidity. The results were however very sensitive to the 
definition of adherence. In resource-limited settings where self-reported adherence is the most 
feasible method for measuring adherence, such as in South Africa, attention should focus on how to 
define adherence in the future. 
 
Improving adherence in this hypertensive patient population can improve BP control, which is 
important with the instigation of initiatives to improve medicine availability in patients with chronic 
diseases in South Africa. Initiatives can include education of patients. However, further research is 
needed to identify additional factors contributing to non-adherence, and to inform relevant future 
strategies to improve adherence. Studies are underway to address this to provide direction to the 
authorities in South Africa and wider as African countries seek to introduce universal health care. With 
the current implementation of the CCMDD and PRDU programmes in South Africa, low medication 
adherence is a concern that needs to be further addressed as this can prevent the achievement of a 
long and healthy life for all.   
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